A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs AGEN-1181 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Agenus
- 02 Apr 2019 According to an Agenus media release, the first patient was dosed by Dr. Steven J. O'Day in this trial.
- 27 Mar 2019 Status changed from not yet recruiting to recruiting.
- 28 Feb 2019 Status changed from planning to not yet recruiting.